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Use of Nanoparticles (NPs) in 
vaccines Components 
Immunogen 







Protective mucosal immune 
responses are most effectively 









The use of nanoparticles in the formulation of 
mucosal vaccines or immunotherapies will allow 
to reduce the dose of immunogen (with or 
without adjuvant), protect and deliver the 
immunogen to the site of interest. 
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Aim 
Biological characterization of nanoparticles 





In vitro characterization of NP in cell lines 
-The interaction with NP is LPS independent  




Biological effect  on murine macrophages RAW 
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Orange: Cito D+NP 
Phagocytosis of the nanoparticle 
       NP 




Biological effect on murine macrophages J774 























Dendritic cell activation 
BMDC are activated with NP: induction of CD86 


























































































Cytochalasin D: phagocytosis inhibitor 
CA-74Me: Catepsine B inhibitor 
Z-VAD-FmKQ: Caspase-1 inhibitor 
Anakinra: receptor antagonist  IL-1RA 
THP1-Myd88 KO 
Is the inflammasome pathway involved? 
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• Inflammasome was activated with IL-1β-production 
• IL-1β-production was TLR-independent 
• Cell activation was Myd88-dependent 
 
Does the nanoparticle have adjuvant properties? 
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Np-OVA induces a Th1 profile 
n=4     NP-OVA 
n=4     OVA+Alum 
n=3     OVA 16 





























































Splenocyte IFN-γ secretion 
NP induced cellular 
immunity 
17 
n=4     NP-OVA 
n=4     OVA+Alum 
n=3     OVA 
 The nanoparticles were internalized by phagocytosis and cells were activated: 
 Induction of CD86+ 
 Production of IL-1β   
 Inflammasome activation in macrophages: non-cannonical activation (without the signal 1) 
 
In vivo adjuvant effect 
 Production of OVA-specific Th1 antibodies 
 Cellular immune response with induction of  IFN-γ-producing CD4 and CD8 T cells 
 
Potential applications: 
 Characterization as a mucosal carrier/adjuvant (IgA?) 
 Use in mucosal immunotherapies for food allergy (OIT and SLIT) (CD4  and CD8 IFN-γ) 
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